Cerebrospinal fluid biomarkers of Alzheimer's disease in Chinese patients: a pilot study

Am J Alzheimers Dis Other Demen. 2013 Dec;28(8):769-75. doi: 10.1177/1533317513504615. Epub 2013 Oct 1.


In view of the paucity of data on cerebrospinal fluid (CSF) biomarkers in Chinese patients, we evaluated the validity of tau, phosphorylated tau 181 (p-tau-181), amyloid β 42 (Aβ42), and Aβ40 proteins in Chinese patients with Alzheimer's disease (AD). We recruited 24 patients with AD, 12 nondemented controls, and 12 patients with non-AD dementia. We found the CSF levels of Aβ42, tau, p-tau, Aβ42-tau, and Aβ42-p-tau ratios, except the Aβ40 protein level, were significantly different among the 3 groups of patients. Patients with AD had higher levels of CSF tau and p-tau but lower levels of Aβ42 proteins, Aβ42-tau, and Aβ42-p-tau ratios than the nondemented controls. In the diagnosis of AD versus nondementia, the sensitivity and specificity of the ratios of Aβ42-tau and Aβ42-p-tau were 96% and 83% versus 92% and 83%, respectively. Only the Aβ42-p-tau ratio showed satisfactory sensitivity and specificity in the diagnosis of AD versus other dementia.

Keywords: Alzheimer’s disease; CSF; Chinese; biomarkers.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Alzheimer Disease / cerebrospinal fluid*
  • Alzheimer Disease / diagnosis
  • Amyloid beta-Peptides / cerebrospinal fluid*
  • Asian People
  • Biomarkers / cerebrospinal fluid
  • Case-Control Studies
  • Cross-Sectional Studies
  • Dementia / cerebrospinal fluid
  • Dementia / diagnosis
  • Female
  • Humans
  • Male
  • Middle Aged
  • Peptide Fragments / cerebrospinal fluid*
  • Phosphorylation
  • Pilot Projects
  • Sensitivity and Specificity
  • tau Proteins / cerebrospinal fluid*
  • tau Proteins / metabolism


  • Amyloid beta-Peptides
  • Biomarkers
  • MAPT protein, human
  • Peptide Fragments
  • amyloid beta-protein (1-40)
  • amyloid beta-protein (1-42)
  • tau Proteins